Informa (LON:INF) Price Target Raised to GBX 1,290

Informa (LON:INF) had its target price raised by Deutsche Bank Aktiengesellschaft from GBX 1,140 to GBX 1,290 in a research note issued to investors on Friday,Digital Look reports. They currently have a buy rating on the stock.

Several other analysts have also weighed in on INF. Citigroup upped their price objective on Informa from GBX 990 to GBX 1,090 and gave the company a “buy” rating in a report on Wednesday, August 12th. JPMorgan Chase & Co. lowered their target price on Informa from GBX 1,300 to GBX 1,285 and set an “overweight” rating on the stock in a report on Thursday, July 2nd. Finally, Berenberg Bank reaffirmed a “buy” rating and set a GBX 1,040 target price on shares of Informa in a report on Thursday. Six investment analysts have rated the stock with a Buy rating. According to MarketBeat, Informa currently has a consensus rating of “Buy” and an average price target of GBX 1,160.

Informa Stock Performance

INF opened at GBX 895.60 on Friday. The business has a 50 day moving average price of GBX 893.22 and a two-hundred day moving average price of GBX 853.78. The company has a debt-to-equity ratio of 64.99, a current ratio of 0.55 and a quick ratio of 1.70. The company has a market capitalization of £11.19 billion, a price-to-earnings ratio of 52.37, a price-to-earnings-growth ratio of 0.75 and a beta of 0.71. Informa has a 1-year low of GBX 719 and a 1-year high of GBX 1,000.

Informa (LON:INF) last issued its quarterly earnings results on Thursday, July 30th. The company reported GBX 26.70 earnings per share (EPS) for the quarter. Informa had a return on equity of 3.90% and a net margin of 5.43%. Research analysts predict that Informa will post 59.32 EPS for the current fiscal year.

Informa Company Profile

Our events, digital products and academic research services connect specialists with knowledge, helping them learn more, know more and do more.

We do this in dozens of specialist markets and subject matter categories, including in Healthcare & Pharma, Technology, Finance, Education, Marketing, Health & Nutrition, Foodservice, and many more.

And we do this through a range of products and services, including major live events, specialist media and content, expert research articles, books and open research platforms, accredited training, buyer discovery services, and digital demand and lead-generation services.